Are open-source approaches to value measurement the wave of the future?

My colleagues Jeroen Jansen, Devin Incerti along with Jeff Curtis think so. In JMCP they write: In the United States, there is an increased interest to understand the value of health technologies. Cost-effectiveness analysis is arguably the most appropriate framework to quantify value and to inform reimbursement decision making regarding medical interventions; however, a thorough…

What Do Value Assessments Miss?

To find out the answer to this question, check out a live webinar on Wednesday, March 13th at 1:30pm EDT led by Dr. Anupam Jena, MD, PhD. Dr. Jena is a Harvard Professor and Precision Health Economics Scientific Advisor. In this unique one-hour webinar, Dr. Jena will outline a broader framework for assessing value to improve identification of not…

ICER and Unsupported Price Increases

The Institute for Clinical and Economic Review (ICER) recently announced that it would annually review treatments with significant price increases to determine if these changes are unsupported by evidence on value. I was recently interviewed by Radar on Specialty Pharmacy to discuss the topic. Jason Shafrin, Ph.D., a senior director of policy and economics at…

Measuring caregiver quality of life

Poor health does not just affect the patient, but also the caregiver who provide physicial, emotional and financial support for these patients. To measure the impact of a disease on patient quality of life, there are a number of metrics one can choose from such as EQ-5D-5L, EQ-5D-VAS, SF-36 among others. Some of these surveys…

New IVI Report Examines Imbalances in Health Care Effectiveness Analyses

The Innovation and Value Initiative (IVI) – a collaboration of academics, patient advocacy organizations, payers, life sciences companies, providers, delivery systems, and other organizations dedicated to finding scientifically credible approaches to measuring value in health care – today released a report examining imbalances in cost-effectiveness analyses (CEAs) across pharmaceuticals, medical/surgical treatments, and mixed procedures. The report, Expanding Cost-Effectiveness…